Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy (Q41257241)

28 September 2017

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy (English)

1 reference

28 September 2017

1 reference

1 reference

1 reference

Maren I Blonk

1

1 reference

28 September 2017

Angela P H Colbers

2

1 reference

28 September 2017

Carmen Hidalgo-Tenorio

3

1 reference

28 September 2017

Kabamba Kabeya

4

1 reference

28 September 2017

Katharina Weizsäcker

5

1 reference

28 September 2017

Annette E Haberl

6

1 reference

28 September 2017

José Moltó

7

1 reference

28 September 2017

David A Hawkins

8

1 reference

28 September 2017

Marchina E van der Ende

9

1 reference

28 September 2017

Andrea Gingelmaier

10

1 reference

28 September 2017

Graham P Taylor

11

1 reference

28 September 2017

Jelena Ivanovic

12

1 reference

28 September 2017

Carlo Giaquinto

13

1 reference

28 September 2017

David M Burger

14

1 reference

28 September 2017

Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network

15

1 reference

28 September 2017

PANNA Network

16

1 reference

28 September 2017

language of work or name

English

0 references

publication date

5 May 2015

1 reference

Clinical Infectious Diseases

28 September 2017

1 reference

28 September 2017

61

1 reference

28 September 2017

809-816

1 reference

28 September 2017

5

1 reference

Epidemiology of HIV infection in women and children: a global perspective

28 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

HIV seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Clinical pharmacology quality assurance for HIV and related infectious diseases research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Raltegravir pharmacokinetics during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Combination antiretroviral use and preterm birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Clinical therapeutics in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

Raltegravir pharmacokinetics in neonates following maternal dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

British HIV Association guidelines for the management of HIV infection in pregnant women 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV366

21 January 2018

Identifiers

DOI

10.1093/CID/CIV366

1 reference

release_jtgwt5kkvrbkxjbl6jmes75hnm

28 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jtgwt5kkvrbkxjbl6jmes75hnm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference